

HCV Directly Acting Antivirals & RBV

Charts revised December 2020. Full information available at www.hep-druginteractions.org

Page 1 of 6

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

Table with 11 columns (DCV, ELB/GZR, G/P, LED/SOF, OBV/PTV/r, OBV/PTV/r+DSV, SMV, SOF, SOF/VEL, SOF/VEL/VOX, RBV) and rows for categories: Anaesthetics & Muscle Relaxants, Analgesics, Anthelmintics, Antiarrhythmics, Antibacterials, and various individual drugs.

For personal use only. Not for distribution.

Table with 11 columns (DCV, ELB/GZR, G/P, LED/SOF, OBV/PTV/r, OBV/PTV/r+DSV, SMV, SOF, SOF/VEL, SOF/VEL/VOX, RBV) and rows for categories: Antibacterials (continued), Anticoagulant, Antiplatelet & Fibrinolytic, and Anticonvulsants.

Key to symbols

Legend table with symbols: red circle (do not coadminister), orange square (significant interaction), yellow triangle (weak interaction), green diamond (no interaction).

Notes

- Further information is available at www.hep-druginteractions.org
Predicted interactions are based on known metabolic pathways and routes of clearance.
Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF. We aim to ensure that information is accurate and consistent with current knowledge and practice.

HCV Directly Acting Antivirals & RBV

Charts revised December 2020. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

| | DCV | ELB/GZR | G/P | LED/SOF | OBV/PTV/r | OBV/PTV/r+DSV | SMV | SOF | SOF/VEL | SOF/VEL/VOX | RBV |
|---|-----|---------|-----|---------|-----------|---------------|-----|-----|---------|-------------|-----|
| Contraceptives and Hormone Replacements (cont) | | | | | | | | | | | |
| Medroxyprogesterone (depot) | ◆ | ◆ | ◆ | ◆ | ▲ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Medroxyprogesterone (oral) | ◆ | ◆ | ◆ | ◆ | ▲ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Medroxyprogesterone/conjugated estrogens (HRT) | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Medroxyprogesterone/estradiol (HRT) | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Norelgestromin/ethinylestradiol (patch) | ◆ | ◆ | ● | ◆ | ● | ● | ◆ | ◆ | ◆ | ● | ◆ |
| Norethisterone (Norethindrone) (depot injection) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Norethisterone (Norethindrone) (POP) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Norethisterone (Norethindrone)/estradiol (HRT) | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Norethisterone (Norethindrone)/ethinylestradiol (COC) | ◆ | ◆ | ● | ◆ | ● | ● | ◆ | ◆ | ◆ | ● | ◆ |
| Norethisterone (Norethindrone)/mestranol (COC) | ◆ | ◆ | ● | ◆ | ● | ● | ◆ | ◆ | ◆ | ● | ◆ |
| Norgestimate/ethinylestradiol (COC) | ◆ | ◆ | ● | ◆ | ● | ● | ◆ | ◆ | ◆ | ● | ◆ |
| Norgestrel/conjugated estrogens (HRT) | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Norgestrel/ethinylestradiol (COC) | ◆ | ◆ | ● | ◆ | ● | ● | ◆ | ◆ | ◆ | ● | ◆ |
| Erectile Dysfunction Agents | | | | | | | | | | | |
| Sildenafil | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Tadalafil | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Vardenafil | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Gastrointestinal Agents | | | | | | | | | | | |
| Aluminium hydroxide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ▲ | ■ | ■ | ◆ |
| Alverine citrate | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Antacids | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ■ | ■ | ◆ |
| Aprepitant | ▲ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Bisacodyl | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cimetidine | ▲ | ◆ | ▲ | ◆ | ■ | ■ | ◆ | ◆ | ■ | ■ | ◆ |
| Cisapride | ◆ | ■ | ■ | ■ | ● | ● | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cyclizine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dantron | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Domperidone | ◆ | ◆ | ■ | ◆ | ● | ● | ◆ | ◆ | ◆ | ◆ | ◆ |
| Droperidol | ◆ | ◆ | ■ | ◆ | ■ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Esomeprazole | ◆ | ◆ | ▲ | ◆ | ▲ | ▲ | ◆ | ◆ | ■ | ■ | ◆ |
| Famotidine | ◆ | ◆ | ▲ | ◆ | ■ | ■ | ◆ | ◆ | ■ | ■ | ◆ |
| Granisetron | ◆ | ▲ | ▲ | ◆ | ■ | ■ | ▲ | ◆ | ◆ | ◆ | ◆ |
| Hyoscine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ispaghula husk | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lactulose | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lansoprazole | ◆ | ◆ | ▲ | ◆ | ▲ | ▲ | ◆ | ◆ | ■ | ■ | ◆ |
| Linaclotide | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Loperamide | ■ | ▲ | ▲ | ■ | ■ | ■ | ◆ | ◆ | ◆ | ▲ | ◆ |
| Lubiprostone | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Macrogol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Mebeverine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Mesalazine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Methylcellulose | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Metoclopramide | ◆ | ◆ | ◆ | ◆ | ● | ● | ◆ | ◆ | ◆ | ◆ | ◆ |
| Naloxegol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Omeprazole | ◆ | ◆ | ▲ | ◆ | ▲ | ▲ | ◆ | ◆ | ■ | ■ | ◆ |
| Ondansetron | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Pantoprazole | ◆ | ◆ | ▲ | ◆ | ▲ | ▲ | ◆ | ◆ | ■ | ■ | ◆ |
| Prucalopride | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Rabeprazole | ◆ | ◆ | ▲ | ◆ | ▲ | ▲ | ◆ | ◆ | ■ | ■ | ◆ |
| Ranitidine | ◆ | ◆ | ▲ | ◆ | ■ | ■ | ◆ | ◆ | ■ | ■ | ◆ |
| Senna | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Simeticone | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Sulfasalazine | ◆ | ◆ | ■ | ◆ | ■ | ■ | ◆ | ◆ | ■ | ● | ◆ |
| Trimebutine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |

| | DCV | ELB/GZR | G/P | LED/SOF | OBV/PTV/r | OBV/PTV/r+DSV | SMV | SOF | SOF/VEL | SOF/VEL/VOX | RBV |
|---|-----|---------|-----|---------|-----------|---------------|-----|-----|---------|-------------|-----|
| HCC Therapies | | | | | | | | | | | |
| Pembrolizumab | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ |
| Regorafenib | ◆ | ▲ | ▲ | ■ | ● | ● | ▲ | ◆ | ■ | ■ | ▲ |
| Hepatitis B Drugs | | | | | | | | | | | |
| Adefovir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Entecavir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lamivudine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ |
| Peginterferon alfa-2a | ◆ | ■ | ■ | ■ | ■ | ■ | ◆ | ◆ | ■ | ■ | ◆ |
| Peginterferon alfa-2b | ◆ | ■ | ■ | ■ | ■ | ■ | ◆ | ◆ | ■ | ■ | ◆ |
| Telbivudine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Tenofovir alafenamide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ | ◆ | ◆ | ■ |
| Tenofovir-DF | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ | ◆ | ■ | ◆ |
| Hepatitis C Drugs (Direct Acting Antivirals) | | | | | | | | | | | |
| Daclatasvir | ◆ | ● | ● | ◆ | ● | ● | ◆ | ◆ | ● | ● | ◆ |
| Elbasvir/Grazoprevir | ● | ■ | ■ | ◆ | ● | ● | ◆ | ◆ | ● | ● | ◆ |
| Glecaprevir/Pibrentasvir | ● | ■ | ■ | ◆ | ● | ● | ◆ | ◆ | ● | ● | ◆ |
| Ledipasvir/Sofosbuvir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| OBV/PTV/r | ● | ● | ● | ◆ | ◆ | n/a | ◆ | ◆ | ● | ● | ◆ |
| OBV/PTV/r + DSV | ● | ● | ● | ◆ | n/a | ◆ | ◆ | ◆ | ● | ● | ◆ |
| Ribavirin | ◆ | ◆ | ◆ | ◆ | n/a | ◆ | ◆ | ◆ | ◆ | ■ | ◆ |
| Simeprevir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ◆ |
| Sofosbuvir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| SOF/Velpatasvir | ● | ● | ● | ◆ | ● | ● | ▲ | ◆ | ◆ | ◆ | ◆ |
| SOF/Velpatasvir/Voxilaprevir | ● | ● | ● | ◆ | ● | ● | ◆ | ◆ | ◆ | ◆ | ■ |

For personal use only. Not for distribution.

Key to symbols

| | |
|---|---|
| ● | These drugs should not be coadministered |
| ■ | Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, Pharmacology Research Labs,
 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Charts revised December 2020. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

| | DCV | ELB/GZR | G/P | LED/SOF | OBV/PTV/r | OBV/PTV/r+DSV | SMV | SOF | SOF/VEL | SOF/VEL/VOX | RBV |
|-------------------------------------|-----|---------|-----|---------|-----------|---------------|-----|-----|---------|-------------|-----|
| Herbals/Supplements/Vitamins | | | | | | | | | | | |
| Aloe vera | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ascorbic acid (Vitamin C) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Black cohosh | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cat's claw (U. tomentosa) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Colecalciferol (Vitamin D3) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cyanocobalamin (B12) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Diosmin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Echinacea | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Eucalyptus globulus | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Folic acid | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Garlic | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ginger (Z. officinale) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ginkgo biloba | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ginseng | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Goldenseal (H. canadensis) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Grape seed extract | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Grapefruit juice | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Green tea (C. sinensis) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Homeopathic remedies | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Inula racemosa | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Iodine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Iron supplements | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Kava kava | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Milk thistle | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Retinol (Vitamin A) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Riboflavin (Vitamin B2) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Serenoa repens | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| St John's wort | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Thiamine (Vitamin B1) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Turmeric (curcumin) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Valerian | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Vitamin E | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |

| | DCV | ELB/GZR | G/P | LED/SOF | OBV/PTV/r | OBV/PTV/r+DSV | SMV | SOF | SOF/VEL | SOF/VEL/VOX | RBV |
|-----------------------------------|-----|---------|-----|---------|-----------|---------------|-----|-----|---------|-------------|-----|
| HIV Drugs | | | | | | | | | | | |
| <i>Entry/Integrase Inhibitors</i> | | | | | | | | | | | |
| Bictegravir/FTC/TAF | ◆ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dolutegravir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dolutegravir/rilpivirine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Elvitegravir/cobi /FTC/TAF | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Elvitegravir/cobi/FTC/TDF | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ibalizumab-uiyk | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Maraviroc | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Raltegravir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| <i>NNRTIs</i> | | | | | | | | | | | |
| Doravirine | ◆ | ◆ | ◆ | ◆ | ▲ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Doravirine/3TC/TDF | ◆ | ◆ | ◆ | ◆ | ▲ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Efavirenz | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Etravirine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Nevirapine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Rilpivirine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Rilpivirine/dolutegravir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Rilpivirine/FTC/TAF | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| <i>NRTIs</i> | | | | | | | | | | | |
| Abacavir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Didanosine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Emtricitabine (FTC) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Emtricitabine + TAF | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Emtricitabine + TDF | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lamivudine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Stavudine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Tenofovir-DP (TDF) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Zidovudine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| <i>Protease Inhibitors</i> | | | | | | | | | | | |
| Atazanavir alone | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Atazanavir/cobicistat | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Atazanavir + ritonavir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Darunavir/cobicistat | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Darunavir/cobi/FTC/TAF | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Darunavir + ritonavir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Fosamprenavir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Indinavir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lopinavir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ritonavir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Saquinavir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Tipranavir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |

For personal use only. Not for distribution.

Key to symbols

| | |
|---|---|
| ● | These drugs should not be coadministered |
| ■ | Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, Pharmacology Research Labs,
 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Charts revised December 2020. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

| | DCV | ELB/GZR | G/P | LED/SOF | OBV/PTV/r | OBV/PTV/r+DSV | SMV | SOF | SOF/VEL | SOF/VEL/VOX | RBV |
|--|-----|---------|-----|---------|-----------|---------------|-----|-----|---------|-------------|-----|
| Hypertension/Heart Failure Agents | | | | | | | | | | | |
| Acebutolol | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Aliskiren | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Ambrisentan | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Amiloride | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Azilsartan | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Benazepril | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Bendroflumethiazide | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Bosentan | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Bumetanide | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Candesartan | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Captopril | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Chlorthalidone | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Chlortalidone | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Cilazapril | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Clevidipine | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Clonidine | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Doxazosin | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Enalapril | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Eplerenone | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Epoprostenol | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Eprosartan | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Fosinopril | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Furosemide | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Hydralazine | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Hydrochlorothiazide | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Iloprost | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Indapamide | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Irbesartan | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Isradipine | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Ivabradine | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Lacidipine | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Lercanidipine | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Lisinopril | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Losartan | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Macitentan | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Methyldopa | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Metolazone | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Moxonidine | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Olmesartan | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Perindopril | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Prazosin | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Quinapril | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Ramipril | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Ranolazine | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Rilmenidine | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Riociguat | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Selexipag | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Sildenafil | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Spiroglactone | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Tadalafil | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Telmisartan | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Torasemide | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Trandolapril | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Treprostinil | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Valsartan | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Xipamide | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Zofenopril | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |

| | DCV | ELB/GZR | G/P | LED/SOF | OBV/PTV/r | OBV/PTV/r+DSV | SMV | SOF | SOF/VEL | SOF/VEL/VOX | RBV |
|----------------------------------|-----|---------|-----|---------|-----------|---------------|-----|-----|---------|-------------|-----|
| Illicit/Recreational | | | | | | | | | | | |
| Alcohol | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Amphetamine | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Cannabis | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Carfentanil | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Cocaine | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Ecstasy (MDMA) | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| GHB (Gamma-hydroxybutyrate) | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Heroin | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| LSD (Lysergic acid diethylamide) | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Mephedrone | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Methamphetamine | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Phencyclidine (PCP) | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Immunosuppressants | | | | | | | | | | | |
| Adalimumab | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Alemtuzumab | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Anakinra | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Azathioprine | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Baricitinib | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Basiliximab | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Brodalumab | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Ciclosporin | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Eculizumab | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Etanercept | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Fingolimod | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Lenalidomide | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Mycophenolate | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Pirfenidone | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Sirolimus | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Tacrolimus | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Upadacitinib | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Lipid Lowering Agents | | | | | | | | | | | |
| Atorvastatin | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Bezafibrate | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Ezetimibe | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Fenofibrate | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Fish oils | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Fluvastatin | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Gemfibrozil | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Lovastatin | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Pitavastatin | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Pravastatin | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Rosuvastatin | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |
| Simvastatin | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ |

For personal use only. Not for distribution.

Key to symbols

| | |
|---|---|
| ● | These drugs should not be coadministered |
| ■ | Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ♦ | No clinically significant interaction expected |

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, Pharmacology Research Labs,
 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

